Plitidepsin for multiple myeloma.
出版信息
Aust Prescr. 2019 Oct;42(5):172-173. doi: 10.18773/austprescr.2019.059. Epub 2019 Sep 13.
Abstract
摘要
相似文献
1
Plitidepsin for multiple myeloma.普利替德生用于治疗多发性骨髓瘤。
Aust Prescr. 2019 Oct;42(5):172-173. doi: 10.18773/austprescr.2019.059. Epub 2019 Sep 13.
2
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.普乐沙福：一种用于治疗复发性/难治性多发性骨髓瘤的潜在新药。
Future Oncol. 2019 Jan;15(2):109-120. doi: 10.2217/fon-2018-0492. Epub 2018 Aug 16.
3
Plitidepsin to treat multiple myeloma.普利替肽素用于治疗多发性骨髓瘤。
Drugs Today (Barc). 2020 May;56(5):337-347. doi: 10.1358/dot.2020.56.5.3135886.
4
Heparin and suramin alter plitidepsin uptake via inhibition of GPCR coupled signaling.肝素和苏拉明通过抑制GPCR偶联信号传导改变普利替肽的摄取。
J Chemother. 2009 Nov;21(5):550-7. doi: 10.1179/joc.2009.21.5.550.
5
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.单独或联合地塞米松每两周 3 小时输注普利替膦治疗复发/难治性多发性骨髓瘤的 II 期临床和药代动力学研究。
Clin Cancer Res. 2010 Jun 15;16(12):3260-9. doi: 10.1158/1078-0432.CCR-10-0469. Epub 2010 Jun 8.
6
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.癌症患者中plitidepsin（Aplidin）的群体药代动力学荟萃分析。
Cancer Chemother Pharmacol. 2009 Jun;64(1):97-108. doi: 10.1007/s00280-008-0841-4. Epub 2008 Oct 22.
7
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.随机 III 期研究（ADMYRE）评估普乐沙福联合地塞米松对比地塞米松单药治疗复发/难治性多发性骨髓瘤的疗效。
Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.
8
Pharmacokinetics and excretion of C-Plitidepsin in patients with advanced cancer.晚期癌症患者中 C-Plitidepsin 的药代动力学和排泄。
Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.
9
Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.液相色谱-串联质谱分析法用于定量测定人血浆、全血和尿液中的普利地昔。
J Pharm Biomed Anal. 2017 Oct 25;145:137-143. doi: 10.1016/j.jpba.2017.06.013. Epub 2017 Jun 21.
10
Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content.普利替肽的细胞结合以及Rac1/JNK信号通路激活取决于膜胆固醇含量。
Mol Pharmacol. 2006 Nov;70(5):1654-63. doi: 10.1124/mol.106.025569. Epub 2006 Aug 23.
本文引用的文献
1
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.随机 III 期研究（ADMYRE）评估普乐沙福联合地塞米松对比地塞米松单药治疗复发/难治性多发性骨髓瘤的疗效。
Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.
2
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.单独或联合地塞米松每两周 3 小时输注普利替膦治疗复发/难治性多发性骨髓瘤的 II 期临床和药代动力学研究。
Clin Cancer Res. 2010 Jun 15;16(12):3260-9. doi: 10.1158/1078-0432.CCR-10-0469. Epub 2010 Jun 8.
Zotero 插件